Kotak Healthcare Fund
- NAV as on 9 Nov 2026
- ₹17.79+3.16%1 day
- Return since launch
- 20.6%
- 52-week range
- ₹12.59 — ₹17.43
- AUM
- ₹825 Cr
Kotak Healthcare Fund is a Sectoral-Pharma equity fund from Kotak Mahindra Mutual Fund with ₹825 Cr under management, launched in 2023. The expense ratio is 2.53% and the SEBI riskometer reading is Very High.
Performance
Kotak Healthcare Fund NAV and returns
Growth of the fund against its category average over the period you pick.
Over 1Y this fund returned +30.9% against +19.9% for its category.
Performance
Returns
How the fund has done against its category and its benchmark.
| Period | Fund | vs category | Category | Benchmark |
|---|---|---|---|---|
| 1Y | 42.5% | +21.7 pts | 20.8% | 29.1% |
| 2Y | 25.8% | +6.8 pts | 19.1% | 17.6% |
| Period | Fund | vs category | Category | Benchmark |
|---|---|---|---|---|
| 1M | 8.0% | −0.4 pts | 8.4% | 8.5% |
| 3M | 6.5% | +2.8 pts | 3.7% | 3.7% |
| 6M | 19.4% | +5.4 pts | 14.0% | 13.6% |
| 1Y | 30.4% | +9.6 pts | 20.8% | 19.4% |
| 2Y | 14.4% | +3.6 pts | 10.8% | 9.5% |
Since launch (20 Nov 2023): 20.6%
Calendar-year returns
Category averageShow as a table
| Period | Fund | vs category | Category |
|---|---|---|---|
| 2025 | -7.3% | −5.3 pts | -2.0% |
| 2024 | 39.1% | −1.8 pts | 40.9% |
Returns over one year are annualised. Shorter periods are absolute.
Costs & terms
Costs and terms
What the fund charges each year, and the rules around putting money in and taking it out.
Costs
2.51%
Expense ratio as on 3 Nov 2026
Charged yearly and already deducted from the NAV.
- Base expense
- 1.97%
- Brokerage
- 0.04%
- Transaction charges
- 0.00%
- Statutory levies
- 0.50%
- Exit load
- 0.5% for redemption within 30 Days
- Lock-in
- None
Terms
- Min SIP
- ₹3,000
- Min lumpsum
- ₹5,000
- Plan
- GROWTH
- Fund type
- OPEN-ENDED
- Benchmark
- NIFTY Healthcare TRI.
- Short-term capital gains
- Returns taxed at 20% if you redeem before 1 year
- Long-term capital gains
- After 1 year, returns above ₹1.25 lakh in a financial year are taxed at 12.5%
Risk
Risk
What the riskometer means for this fund, and how its ratios sit against the category.
Your principal is treated as being at very high risk — typically small cap, sectoral and thematic equity schemes.
Portfolio
Kotak Healthcare Fund portfolio
Portfolio as of 30 Sep 2026
Asset allocation
- Equity98.7%
- Other1.3%
Market cap split
- Large33.9%
- Mid19.9%
- Small46.2%
- P/E
- 50.62
- P/B
- 6.55
Top holdings
| Holding | Sector | Weight | Value | 3M chg | 6M chg | 1Y chg |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Healthcare | 13.21% | ₹109 Cr | +13.73% | +13.91% | +13.05% |
| Divi's Laboratories Ltd. | Healthcare | 9.35% | ₹77.12 Cr | +5.33% | +6.05% | +4.90% |
| Molbio Diagnostics Ltd. | Healthcare | 5.08% | ₹41.88 Cr | — | — | — |
| Torrent Pharmaceuticals Ltd. | Healthcare | 4.65% | ₹38.40 Cr | — | — | — |
| Acutaas Chemicals Ltd. | Healthcare | 4.17% | ₹34.43 Cr | +5.20% | +5.09% | +2.56% |
| Max Healthcare Institute Ltd. | Healthcare | 3.61% | ₹29.75 Cr | +5.99% | +6.96% | +7.33% |
| Cipla Ltd. | Healthcare | 3.26% | ₹26.92 Cr | +4.32% | +3.32% | +5.51% |
| Park Medi World Ltd. | Healthcare | 3.17% | ₹26.12 Cr | +3.97% | +3.48% | — |
| Gland Pharma Ltd. | Healthcare | 3.16% | ₹26.09 Cr | +2.21% | +2.11% | +3.00% |
| Yatharth Hospital & Trauma Care Services Ltd. | Healthcare | 3.12% | ₹25.71 Cr | +3.15% | +1.26% | +1.44% |
| Apollo Hospitals Enterprise Ltd. | Healthcare | 2.97% | ₹24.50 Cr | +2.56% | +3.35% | +4.23% |
| Sai Life Sciences Ltd. | Healthcare | 2.96% | ₹24.39 Cr | +2.91% | +3.08% | +2.23% |
| Laurus Labs Ltd. | Healthcare | 2.88% | ₹23.76 Cr | +2.24% | — | — |
| Mankind Pharma Ltd. | Healthcare | 2.73% | ₹22.53 Cr | +3.38% | +1.72% | +2.62% |
| Krishna Institute of Medical Sciences Ltd | Healthcare | 2.71% | ₹22.39 Cr | +3.09% | +2.81% | +3.02% |
| Marksans Pharma Ltd. | Healthcare | 2.44% | ₹20.14 Cr | +2.41% | +1.77% | +1.78% |
| Anthem Biosciences Ltd. | Healthcare | 2.34% | ₹19.32 Cr | +2.27% | +2.37% | +2.79% |
| Fortis Healthcare Ltd. | Healthcare | 2.33% | ₹19.25 Cr | +4.02% | +4.67% | +4.18% |
| Prasol Chemicals Ltd. | Chemicals | 2.24% | ₹18.48 Cr | — | — | — |
| Ajanta Pharma Ltd. | Healthcare | 1.97% | ₹16.29 Cr | +2.37% | +2.66% | +2.33% |
| Rubicon Research Ltd. | Healthcare | 1.96% | ₹16.19 Cr | +2.07% | +1.75% | — |
| Emcure Pharmaceuticals Ltd. | Healthcare | 1.77% | ₹14.57 Cr | +1.49% | +1.80% | — |
| Aurobindo Pharma Ltd. | Healthcare | 1.72% | ₹14.21 Cr | +2.33% | +2.80% | +2.36% |
| Viyash Scientific Limited | Healthcare | 1.71% | ₹14.15 Cr | — | — | — |
| Orchid Pharma Ltd. | Healthcare | 1.57% | ₹12.96 Cr | +1.72% | +1.09% | +1.51% |
| CORONA Remedies Ltd. | Healthcare | 1.52% | ₹12.56 Cr | +1.74% | +1.93% | — |
| Innova Captab Ltd. | Healthcare | 1.41% | ₹11.60 Cr | +1.11% | +1.20% | +1.75% |
| Jubilant Ingrevia Ltd. | Chemicals | 1.35% | ₹11.10 Cr | — | — | — |
| Others | Others | 1.31% | ₹10.71 Cr | -0.58% | -1.18% | -0.48% |
| Jubilant Pharmova Ltd. | Healthcare | 1.25% | ₹10.32 Cr | +1.93% | +2.49% | +3.26% |
| Rainbow Children's Medicare Ltd. | Healthcare | 1.11% | ₹9.20 Cr | +1.46% | +1.13% | +1.36% |
| Dr. Lal Pathlabs Ltd. | Healthcare | 1.06% | ₹8.74 Cr | +1.07% | — | — |
| Zydus Lifesciences Ltd. | Healthcare | 1.06% | ₹8.72 Cr | +1.64% | +1.38% | +1.69% |
| Lupin Ltd. | Healthcare | 0.98% | ₹8.12 Cr | +2.32% | +4.19% | +3.91% |
| Metropolis Healthcare Ltd. | Healthcare | 0.98% | ₹8.13 Cr | +1.19% | — | — |
| Pfizer Ltd. | Healthcare | 0.89% | ₹7.36 Cr | — | — | — |
Sectors
Instruments
Recent changes
| Holding | From | To | Weight |
|---|---|---|---|
| Prasol Chemicals Ltd. | 0.00% | 2.24% | +2.24% |
| Sun Pharmaceutical Industries Ltd. | 13.96% | 13.21% | -0.75% |
| Max Healthcare Institute Ltd. | 4.34% | 3.61% | -0.73% |
| Fortis Healthcare Ltd. | 2.95% | 2.33% | -0.62% |
| Molbio Diagnostics Ltd. | 4.53% | 5.08% | +0.55% |
| Cipla Ltd. | 3.67% | 3.26% | -0.41% |
| Rubicon Research Ltd. | 2.37% | 1.96% | -0.41% |
| Laurus Labs Ltd. | 2.49% | 2.88% | +0.39% |
| Innova Captab Ltd. | 1.08% | 1.41% | +0.33% |
| Viyash Scientific Limited | 2.01% | 1.71% | -0.30% |
| Apollo Hospitals Enterprise Ltd. | 3.25% | 2.97% | -0.28% |
| Others | -1.43% | -1.70% | -0.27% |
| Pfizer Ltd. | 1.16% | 0.89% | -0.27% |
| Acutaas Chemicals Ltd. | 3.91% | 4.17% | +0.26% |
| Krishna Institute of Medical Sciences Ltd | 2.46% | 2.71% | +0.25% |
| Emcure Pharmaceuticals Ltd. | 1.57% | 1.77% | +0.20% |
| Park Medi World Ltd. | 3.36% | 3.17% | -0.19% |
| Rainbow Children's Medicare Ltd. | 1.29% | 1.11% | -0.18% |
| Laxmi Dental Ltd. | 0.17% | 0.00% | -0.17% |
| Lupin Ltd. | 1.14% | 0.98% | -0.16% |
| Metropolis Healthcare Ltd. | 1.14% | 0.98% | -0.16% |
| Aurobindo Pharma Ltd. | 1.57% | 1.72% | +0.15% |
| Ajanta Pharma Ltd. | 2.11% | 1.97% | -0.14% |
| Jubilant Ingrevia Ltd. | 1.49% | 1.35% | -0.14% |
| Yatharth Hospital & Trauma Care Services Ltd. | 3.25% | 3.12% | -0.13% |
| Gland Pharma Ltd. | 3.04% | 3.16% | +0.12% |
| Mankind Pharma Ltd. | 2.84% | 2.73% | -0.11% |
| Jubilant Pharmova Ltd. | 1.15% | 1.25% | +0.10% |
| Divi's Laboratories Ltd. | 9.25% | 9.35% | +0.10% |
| Torrent Pharmaceuticals Ltd. | 4.75% | 4.65% | -0.10% |
| CORONA Remedies Ltd. | 1.60% | 1.52% | -0.08% |
| Sai Life Sciences Ltd. | 3.04% | 2.96% | -0.08% |
| Marksans Pharma Ltd. | 2.51% | 2.44% | -0.07% |
| Orchid Pharma Ltd. | 1.64% | 1.57% | -0.07% |
| Zydus Lifesciences Ltd. | 1.13% | 1.06% | -0.07% |
| Dr. Lal Pathlabs Ltd. | 1.11% | 1.06% | -0.05% |
| Anthem Biosciences Ltd. | 2.33% | 2.34% | +0.01% |
Compare
Similar funds
The rest of the category, so this fund’s numbers have something to sit against.
| Fund | AUM | Expense | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| Category average | ₹2,934 Cr | 1.89% | 36.5% | 20.8% | 21.6% |
 SBI Healthcare Opportunities Fund | ₹6,067 Cr | 1.98% | 35.0% | 19.9% | 22.6% |
 HDFC Pharma And Healthcare Fund | ₹3,501 Cr | 2.11% | 39.6% | 25.8% | — |
 Mirae Asset Healthcare Fund | ₹3,494 Cr | 2.01% | 37.3% | 20.2% | 21.1% |
 UTI Healthcare Fund | ₹1,430 Cr | 2.21% | 30.6% | 18.4% | 21.1% |
 ICICI Prudential Nifty Pharma Index Fund | ₹177 Cr | 1.13% | 39.9% | 19.9% | — |
About
About this fund
The scheme’s own words, its benchmark and the people running it.
Investment objective
The scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly Pharma, Healthcare, and allied sectors.
Fund managers
- Abhishek BisenMr. Bisen is a BA and MBA in Finance.Prior to joining Kotak AMC, he was working with Securities Trading Corporation Of India Ltd where he was looking at Sales & Trading of Fixed Income Products apart from doing Portfolio Advisory. His earlier assignments also include 2 years of merchant banking experience with a leading merchant banking firm.
- Dhananjay TikarihaMr. Tikariha has done B.Tech, M. Tech from IIT Madras and PGDM (Finance & Marketing) from IIM LucknowPrior to joining Kotak Mahindra Mutual Fund, he has worked with IDFC First Bank
Tools
Return calculator
What ₹10,000 a month in this fund would have grown to over each period, based on its past returns.
| Over the past | Total investment | Would’ve become | Growth | Returns |
|---|---|---|---|---|
| 6 months19.40% absolute | ₹60,000 | ₹71,640 | 19.40% | |
| 1 year30.40% annualised | ₹1,20,000 | ₹1,41,717 | 18.10% |
Returns for 1 year and longer are annualised (CAGR); 6-month figures are absolute. Past returns are not a forecast.
How this is calculated
Each monthly instalment grows at the fund’s annualised return ÷ 12 per month until the end of the period, the same formula as our SIP calculator.
The amount compounds once a year at the fund’s CAGR for that period, the same formula as our lumpsum calculator.
Questions
Frequently asked questions
The things people ask about this scheme.